FDA Approves Reclast(R) to Prevent Osteoporosis in Postmenopausal Women

Reclast(R) (zoledronic acid)Injection has been approved by the FDA asthe first and only therapy to prevent postmenopausal osteoporosis for twoyears with a single dose. Reclast is already approved as a once-yearlyinfusion for the treatment of postmenopausal osteoporosis. The FDA decision is based on a study involving more than 500postmenopausal women with osteopenia, or low bone mass, showing that a singleinfusion of Reclast significantly increased bone mineral density (BMD) at twoyears compared to placebo